NHT102 (azacitidine)

NHT102 is an investigational dry powder formulation of the epigenetic modulator azacitidine (5-azacytidine) developed by Nob Hill Therapeutics for the treatment of advanced non-small cell lung cancer (NSCLC). It is designed to be delivered directly to the lungs using Nob Hill's proprietary DryNeb dry powder inhalation system, which allows for high-dose delivery under normal tidal breathing conditions. By delivering azacitidine directly to the respiratory tract, NHT102 aims to achieve high local drug concentrations in the lungs to reverse tumor-promoting epigenetic methylation and reprogram the cancer genome, while minimizing systemic exposure and associated toxicities. NHT102 is being evaluated in a Phase 1/2 clinical trial for patients with advanced NSCLC confined to the thoracic region.

Other names

5-AZA5-azacytidineaerosolized 5-azacytidineaerosolized5-azacytidineaerosolized-5-azacytidineaerosolized azacitidineazacitidineinhaled 5-azacytidineinhaled5-azacytidineinhaled-5-azacytidineinhaled azacitidine